




ECNP New Frontiers Meeting 2027

Prospectus for supporters



The ECNP New Frontiers Meeting 2027

The ECNP New Frontiers Meeting is a unique platform, bringing together 150 key opinion leaders from the research, clinical, pharma, regulatory, and patient communities from around the world for one a half days of focused exchange and discussion, hosted by Europe's leading independent scientific association for the science and treatment of disorders of the brain.

Supporting the meeting offers companies and organisations with an investment in brain health and neuropsychiatric treatment development priority recognition in ECNP's global stakeholder campaign to set psychiatric treatment research on a more scientifically robust basis and to open the way to more viable drug discovery and development and better patient outcomes.

AI in mental health: transforming diagnostics, therapeutics and care

21-22 March 2027, Nice, France

The 2027 ECNP New Frontiers Meeting will focus on one of the most consequential questions in mental health today: what can artificial intelligence realistically deliver for patients, clinicians and health systems and where are its limits?

While AI is advancing rapidly across psychiatry and neuroscience, the translation into routine clinical care remains uncertain. Promising developments in areas such as AI-supported clinical interviews, digital phenotyping, and data-driven biomarkers are raising expectations for earlier diagnosis, better stratification of patients, and more personalised treatment. At the same time, robust evidence of clinical impact is still emerging, and key challenges around validation, interpretability, and implementation remain unresolved.

This meeting will bring together leading researchers, clinicians, industry partners, regulators, and people with lived experience to critically examine where AI adds genuine value in mental health care. Particular attention will be given to diagnostic and treatment support tools, the development and clinical utility of AI-derived biomarkers, and how these approaches might be integrated into real-world psychiatric practice.

Importantly, the programme will also address the risks and limitations of AI in mental health, including bias, over-reliance on automated systems, data governance, and patient safety. The aim is not to promote technology for its own sake, but to assess what is clinically meaningful, what is not yet ready, and what evidence is still needed.

In line with the ECNP New Frontiers format, the meeting provides a neutral, precompetitive space for open discussion across disciplines, with a clear focus on translation into better outcomes for patients.

When:	21-22 March 2027
Where:	Radisson Blu Hotel Nice 223 Promenade Des Anglais, Nice, France
Audience:	150 opinion leaders from the research, clinical, pharma, regulatory, HTA, payer, patient advocacy and policy-making communities
Participation:	By application and selection
Website:	https://www.ecnp.eu/meetings/new-frontiers-meeting/

About ECNP

ECNP is Europe's leading independent forum for the science of CNS treatments. The ECNP Congress showcases the world's best disease-oriented brain research, annually attracting some 7,600 psychiatrists, neuroscientists, neurologists and psychologists from around the world. The College's wide range of scientific and educational activities, programmes and events make it one of the largest non-institutional supporters of applied and translational neuroscience research and education in Europe. A founder member of the European Brain Council, ECNP also has extensive outreach experience through its press activities, epidemiological and policy studies, and engagement with stakeholders across the treatment lifecycle and throughout the wider brain health community.

Provisional programme

SUNDAY 21 MARCH 2027

- 13.30-14.00 Registration
- 14.00-14.15 **Welcome and opening**
- 14.15-15.00 **Keynote lecture**
Tom Insel, US
- 15.00-15.15 Discussion & Q&A
- 15.15-15.45 Break
- 15.45-18.30 **Session 1: AI-powered therapeutics: LLMs and AI-driven mental health interventions**
- 15.45-16.10 Foundations of AI and machine learning: concepts and nomenclature
- 16.10-16.35 Rule-based AI vs LLMs: deterministic and non-deterministic approaches in mental health
- 16.35-17.00 From generic to personalized: the evolution of LLM-based psychotherapy
- 17.00-17.25 From promise to precaution: ethical considerations for AI-driven mental health interventions
- 17.25-17.45
- 17.45-18.30 Panel discussion and conclusion day 1
- 18.30-19.30 **Networking drinks**
- 19.30- 22.00 Networking dinner

MONDAY 22 MARCH 2027

- 08.30-11.45 **Session 2: AI-derived biomarkers: transforming diagnosis and neuropsychiatric drug development**
- 08.30-08.55 From diagnostic categories to data-driven biotypes
- 08.55-09.20 AI biomarkers for patient enrichment in neuropsychiatric trials
- 09.20-09.45 AI-enabled precision trials: matching the right patient to the right mechanism
- 09.45-10.10 What makes an AI biomarker clinically and regulatorily useful?
- 10.10-10.45 Break
- 10.45-11.45 Panel Discussion
- 11.45-15.00 **Session 3: AI in clinical trials: smarter patient selection, study design and regulatory innovation**
- 11.45-12.10 Transforming clinical trials with AI: opportunities from an industry perspective
- 12.10-12.35 Navigating the regulatory landscape for AI in clinical trials
- 12.35-13.35 Lunch
- 13.35-14.00 Digital and AI-derived biomarkers as regulatory-grade endpoints
- 14.00-14.55 Panel Discussion
- 14.55-15.00 **Conclusion and closing**

The ECNP New Frontiers Concept

Neuroscience is facing a crisis in the translation of fundamental advances into new treatments. The crisis has seen a significant slowing -down in the development of new and better therapies, and widespread disinvestment from the field, especially in Europe. The ECNP New Frontiers Meeting was launched to help tackle this critical challenge. As Europe's leading independent scientific association for the science and treatment of disorders of the brain, ECNP is in a unique position to provide a neutral, precompetitive platform for the exchange of insights and ideas across the spectrum of CNS research and development.



How to support the meeting

Proposal to change: ECNP invites organisations and companies interested in advancing the science and application of artificial intelligence in mental health to join us in supporting this meeting.

Contributing Partner (€30,000)

For a €30,000 contribution, Contributing Partners will receive:

- Acknowledgement statement and prominent logo placement in the meeting informational material:
 - Meeting website
 - Introductory and closing slides
 - Supporter banner displayed at the meeting venue
- Two complimentary in-person registrations

SME supporter (€5,000)

An SME has less than 250 staff members and a turnover less than € 50 million (or balance sheet of less than € 43 million).¹

For a €5,000 contribution, SME Supporters will receive:

- Acknowledgement statement and logo placement in the meeting informational material, with logos displayed in a smaller format than those of Contributing Partners:
 - Meeting website
 - Introductory and closing slides
 - Supporter banner displayed at the meeting venue
- No complimentary registrations included

For further details please contact ECNP at **meetings-nice@ecnp.eu**.

Companies and organisations supporting the meeting should be aware that the ECNP New Frontiers Meeting is a multi-supporter event. The nature of the stakeholder interaction that is at the heart of the meeting precludes sole-sponsor arrangements.

¹ https://single-market-economy.ec.europa.eu/smes/sme-fundamentals/sme-definition_en.